AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19184087 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-running-session trial (T2) - Continuous 10-km run (70% peak VO2 velocity) followed by 10 x 1 km interval run (90% peak VO2 velocity) 12 hours later
Number of subjects: 10
Study 19184087 — intervention group
Group type: EXPERIMENTAL
Intervention: Both trials (T1 and T2)
Number of subjects: 10
Study 16430570 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway-Classic (LMA)
Number of subjects: 60
Study 16430570 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable Soft Seal Laryngeal Mask
Number of subjects: 60
Study 15497716 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 0
Study 11524064 — intervention group
Group type: EXPERIMENTAL
Intervention: TTE (Transthoracic Echocardiography)
Number of subjects: 57
Study 11524064 — intervention group
Group type: EXPERIMENTAL
Intervention: TEE (Transesophageal Echocardiography)
Number of subjects: 57
Study 11524064 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual assessment of TTE images
Number of subjects: 57
Study 9029752 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-g oral dose of vigabatrin
Number of subjects: 59
Study 9029752 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-g and 4-g oral doses of vigabatrin
Number of subjects: 59
Study 9029752 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75-g dose of vigabatrin in renal failure patients
Number of subjects: 59
Study 8498730 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine 60 mg/pseudoephedrine hydrochloride 120 mg (T/Ps)
Number of subjects: 178
Study 8498730 — intervention group
Group type: EXPERIMENTAL
Intervention: clemastine fumarate 1.34 mg/phenylpropanolamine 75 mg (C/Ph)
Number of subjects: 178
Study 3278574 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg sublingual nifedipine (group 1)
Number of subjects: 149
Study 3278574 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group 2)
Number of subjects: 149
Study 3278574 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (group 1)
Number of subjects: 149
Study 31957334 — intervention group
Group type: EXPERIMENTAL
Intervention: TDM-guided dosing
Number of subjects: 70
Study 31957334 — intervention group
Group type: COMPARATOR
Intervention: Current practice (160 mg/m2)
Number of subjects: 70
Study 31455386 — intervention group
Group type: COMPARATOR
Intervention: Propofol at 0 μg.ml ‐1
Number of subjects: 30
Study 31455386 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at 0.5 μg.ml ‐1
Number of subjects: 30
Study 31455386 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at 1.0 μg.ml ‐1
Number of subjects: 30
Study 27496969 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA hypermethylation analysis of biomarkers RASSF1A, 3OST2, PRDM14
Number of subjects: 284
Study 27496969 — intervention group
Group type: EXPERIMENTAL
Intervention: RASSF1A
Number of subjects: 284
Study 27496969 — intervention group
Group type: COMPARATOR
Intervention: Sputum cytology
Number of subjects: 284
Study 26028494 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 0
Study 26028494 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone
Number of subjects: 0
Study 26028494 — intervention group
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Number of subjects: 0
Study 26028494 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Number of subjects: 0
Study 26028494 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 0
Study 23459398 — intervention group
Group type: EXPERIMENTAL
Intervention: 4PCP training program (active learning arm and clinical support arm)
Number of subjects: 31
Study 23459398 — intervention group
Group type: EXPERIMENTAL
Intervention: 4PCP training program
Number of subjects: 31
Study 21688873 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 205
Study 21688873 — intervention group
Group type: COMPARATOR
Intervention: Educational Feedback Control (EFC)
Number of subjects: 205
Study 18463125 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib-MenC-TT
Number of subjects: 476
Study 18463125 — intervention group
Group type: COMPARATOR
Intervention: MenC-CRM197
Number of subjects: 476
Study 21355149 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion combined with Alendronate
Number of subjects: 55
Study 21355149 — intervention group
Group type: COMPARATOR
Intervention: Alendronate only
Number of subjects: 55
Study 16108508 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anti-histamine/decongestant eye drops
Number of subjects: 200
Study 16108508 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (washing eyes with cold water and applying ice packs)
Number of subjects: 200
Study 12126869 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (400‐800 mg/day, n = 339)
Number of subjects: 612
Study 12126869 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (15‐20 mg/day, n = 160)
Number of subjects: 612
Study 12126869 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (8 mg/day, n = 113)
Number of subjects: 612
Study 9641175 — intervention group
Group type: EXPERIMENTAL
Intervention: AN140
Number of subjects: 16
Study 7806817 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous splinting (early treatment)
Number of subjects: 40
Study 7806817 — intervention group
Group type: COMPARATOR
Intervention: Continuous splinting (delayed treatment)
Number of subjects: 40
Study 2699608 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranylcypromine (5 mg once a day)
Number of subjects: 13
Study 2699608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 766567 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 12
Study 766567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30769272 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin with/without eicosapentaenoic acid
Number of subjects: 140
Study 30579342 — intervention group
Group type: COMPARATOR
Intervention: Tetracaine mucilage instilled into the urethra and applied to the catheter
Number of subjects: 60
Study 30579342 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine mucilage in combination with image illustration on CRBD
Number of subjects: 60
Study 27098676 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted invitation materials
Number of subjects: 2000
Study 27098676 — intervention group
Group type: COMPARATOR
Intervention: Control invitation materials
Number of subjects: 2000
Study 25415158 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (450 mg per day)
Number of subjects: 64
Study 25415158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 22776103 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-session home-based therapeutic intervention program (18 one-hour sessions in three 6-week blocks) targeting language development domains.
Number of subjects: 200
Study 22776103 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-session home-based therapeutic intervention program
Number of subjects: 200
Study 22776103 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 200
Study 19036079 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside (ara‐C) therapy with IDA‐FLAG (ara‐C = 7590 mg/m2)
Number of subjects: 457
Study 19036079 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside (ara‐C) therapy with IDA‐DCTER (ara‐C = 800 mg/m2)
Number of subjects: 457
Study 19036079 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside (ara‐C) therapy with IDA‐FLAG
Number of subjects: 457
Study 19036079 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside (ara‐C) therapy
Number of subjects: 457
Study 17935765 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol/fluticasone propionate combination (SFC)
Number of subjects: 3416
Study 17935765 — intervention group
Group type: COMPARATOR
Intervention: fluticasone propionate (FP)
Number of subjects: 3416
Study 15300807 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum PSA < 3 ng/ml
Number of subjects: 80458
Study 15300807 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum PSA 3.0-3.9 ng/ml with benign digital rectal examination or free total PSA ratio > or = 0.16
Number of subjects: 80458
Study 11253317 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked practice with simple relative timing patterns
Number of subjects: 0
Study 11253317 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked practice with complex relative timing patterns
Number of subjects: 0
Study 11253317 — intervention group
Group type: EXPERIMENTAL
Intervention: Random practice
Number of subjects: 0
Study 11253317 — intervention group
Group type: COMPARATOR
Intervention: Blocked practice
Number of subjects: 0
Study 9638987 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR analysis of fine needle aspiration (FNA) samples
Number of subjects: 49
Study 9638987 — intervention group
Group type: COMPARATOR
Intervention: FNA morphological examination
Number of subjects: 49
Study 9638987 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR analysis when samples were inadequate for cytologic examination
Number of subjects: 49
Study 8208391 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine (35 mg) after saline infusion
Number of subjects: 14
Study 8208391 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (500 micrograms) after saline infusion
Number of subjects: 14
Study 8208391 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 14
Study 2592580 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (90 mg every 8 hours)
Number of subjects: 12
Study 2592580 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg every 8 hours)
Number of subjects: 12
Study 2592580 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (200 mg every 12 hours)
Number of subjects: 12
Study 2592580 — intervention group
Group type: COMPARATOR
Intervention: Placebo (every 12 hours)
Number of subjects: 12
Study 2592580 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Number of subjects: 12
Study 4827383 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu 200
Number of subjects: 0
Study 4827383 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu 300
Number of subjects: 0
Study 4827383 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu 380A
Number of subjects: 0
Study 30048414 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated sunlight (1.3× standard erythemal dose in T‐shirt and shorts, three times per week for 4 wk and then once per week for 8 wk)
Number of subjects: 137
Study 30048414 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D3 (1000 IU·d for 4 wk and then 400 IU·d for 8 wk)
Number of subjects: 137
Study 30048414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 28853117 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurostimulation (NS)
Number of subjects: 21
Study 28853117 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US)
Number of subjects: 21
Study 26190666 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed physiotherapy with monitoring device during pendulum exercises
Number of subjects: 24
Study 26190666 — intervention group
Group type: COMPARATOR
Intervention: Uninformed home rehabilitation
Number of subjects: 24
Study 23177758 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-jaw procedure
Number of subjects: 24
Study 23177758 — intervention group
Group type: COMPARATOR
Intervention: Double-jaw procedure
Number of subjects: 24
Study 23177758 — intervention group
Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 24
Study 21094321 — intervention group
Group type: EXPERIMENTAL
Intervention: Motorcycle simulator training
Number of subjects: 410
Study 21094321 — intervention group
Group type: COMPARATOR
Intervention: Passive training based on a road safety lesson
Number of subjects: 410
Study 18683001 — intervention group
Group type: EXPERIMENTAL
Intervention: SDA-SBO (24 ml/day providing approximately 3.7 g SDA)
Number of subjects: 45
Study 18683001 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA (approximately 1 g/day)
Number of subjects: 45
Study 18683001 — intervention group
Group type: COMPARATOR
Intervention: Regular SBO (control group)
Number of subjects: 45
Study 17062681 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab and IL‐12 (arm A)
Number of subjects: 58
Study 17062681 — intervention group
Group type: COMPARATOR
Intervention: Rituximab followed by IL‐12 after progression (arm B)
Number of subjects: 58
Study 12452400 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 53
Study 12452400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 12452400 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine butyl-bromide
Number of subjects: 53
Study 10508799 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI alone
Number of subjects: 10
Study 10508799 — intervention group
Group type: COMPARATOR
Intervention: MDI with holding chamber
Number of subjects: 10
Study 7554393 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 administered by daily subcutaneous injection for 7 days at a dose level of 1, 3, or 10 micrograms/kg/day
Number of subjects: 8
Study 2254511 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CB)
Number of subjects: 44
Study 2254511 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control (WL)
Number of subjects: 44
Study 2254511 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control (WL) after treatment
Number of subjects: 44
Study 2254511 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CB) at 10-week follow-up
Number of subjects: 44
Study 7437255 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxyfedrine (maximum dose 32 mg three times daily)
Number of subjects: 30
Study 7437255 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (maximum dose 120 mg three times daily)
Number of subjects: 30
Study 7437255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30058174 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrioventricular optimization algorithm (SmartDelay™)
Number of subjects: 726
Study 30058174 — intervention group
Group type: COMPARATOR
Intervention: Fixed AV Delay of 120 ms with biventricular pacing
Number of subjects: 726
Study 28464364 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR and web‐based intervention
Number of subjects: 99
Study 28464364 — intervention group
Group type: COMPARATOR
Intervention: MMR
Number of subjects: 99
Study 26278037 — intervention group
Group type: EXPERIMENTAL
Intervention: POD 3 drain removal
Number of subjects: 106
Study 26278037 — intervention group
Group type: COMPARATOR
Intervention: POD 5 drain removal
Number of subjects: 106
Study 26278037 — intervention group
Group type: EXPERIMENTAL
Intervention: POD 1 drain and serum amylase values
Number of subjects: 106
Study 26278037 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate/high risk patients
Number of subjects: 106
Study 23030836 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive video gaming (IVG) using Nintendo Wii Fit for 3 weeks
Number of subjects: 14
Study 21088453 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil supplementation
Number of subjects: 13
Study 21088453 — intervention group
Group type: COMPARATOR
Intervention: Safflowerseed oil supplementation
Number of subjects: 13
Study 18323317 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted decision making (CADM) using a handheld device
Number of subjects: 4
Study 18323317 — intervention group
Group type: COMPARATOR
Intervention: No CADM technology (control)
Number of subjects: 4
Study 17158441 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol (20 mg)
Number of subjects: 40
Study 17158441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 14623840 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 101
Study 14623840 — intervention group
Group type: COMPARATOR
Intervention: Bi-level Positive Airway Pressure (BiPAP)
Number of subjects: 101
Study 14623840 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) for APO subgroup
Number of subjects: 101
Study 14623840 — intervention group
Group type: COMPARATOR
Intervention: Bi-level Positive Airway Pressure (BiPAP) for APO subgroup
Number of subjects: 101
Study 10945421 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder strapping for six weeks in addition to standard physiotherapy
Number of subjects: 98
Study 10945421 — intervention group
Group type: COMPARATOR
Intervention: No strapping (control group)
Number of subjects: 98
Study 9234881 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 41
Study 9234881 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol abuse
Number of subjects: 41
Study 9234881 — intervention group
Group type: EXPERIMENTAL
Intervention: Idiopathic osteonecrosis
Number of subjects: 41
Study 9234881 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (healthy donors)
Number of subjects: 41
Study 9234881 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (bone-marrow grafting for non-union)
Number of subjects: 41
Study 8134738 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox model analysis
Number of subjects: 0
Study 8134738 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification and Regression Tree (CART) technique
Number of subjects: 0
Study 2824365 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term dietary sodium restriction in normotensive adolescents
Number of subjects: 508
Study 2824365 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term dietary intervention in hypertensive adults
Number of subjects: 508
Study 2824365 — intervention group
Group type: COMPARATOR
Intervention: Lithium countertransport in hypertensive adults treated with antihypertensive medications
Number of subjects: 508
Study 2824365 — intervention group
Group type: COMPARATOR
Intervention: Lithium countertransport in normotensive adults
Number of subjects: 508
Study 2824365 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-stimulated lithium countertransport
Number of subjects: 508
Study 31036563 — intervention group
Group type: EXPERIMENTAL
Intervention: EX+BR (exercise + breaks): sitting (1 hour), moderate-intensity walking (30 min), sitting interrupted every 30 min with 3 min of light-intensity walking (6.5 hours)
Number of subjects: 67
Study 31036563 — intervention group
Group type: EXPERIMENTAL
Intervention: EX+SIT (exercise + sitting): sitting (1 hour), moderate-intensity walking (30 min), uninterrupted sitting (6.5 hours)
Number of subjects: 67
Study 31036563 — intervention group
Group type: EXPERIMENTAL
Intervention: EX+SIT (exercise + sitting)
Number of subjects: 67
Study 31036563 — intervention group
Group type: EXPERIMENTAL
Intervention: EX+BR (exercise + breaks)
Number of subjects: 67
Study 31036563 — intervention group
Group type: COMPARATOR
Intervention: SIT (sitting): uninterrupted sitting (8 hours, control)
Number of subjects: 67
Study 29884603 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Mom Zone Intervention (adaptive intervention with step-ups in dosages)
Number of subjects: 31
Study 29884603 — intervention group
Group type: COMPARATOR
Intervention: Standard care control group
Number of subjects: 31
Study 26507862 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 mg of rhBMP‐7 (Osigraft OP1) on a type I collagen carrier
Number of subjects: 11
Study 25479219 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal endoscopic medial maxillectomy (for recurrent cases)
Number of subjects: 51
Study 25479219 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal endoscopic medial maxillectomy (for primary cases)
Number of subjects: 51
Study 25479219 — intervention group
Group type: COMPARATOR
Intervention: Transnasal endoscopic resection
Number of subjects: 51
Study 25479219 — intervention group
Group type: COMPARATOR
Intervention: Caldwell-Luc operation
Number of subjects: 51
Study 25479219 — intervention group
Group type: EXPERIMENTAL
Intervention: Redo transnasal endoscopic medial maxillectomy (Caldwell-Luc group)
Number of subjects: 51
Study 25479219 — intervention group
Group type: EXPERIMENTAL
Intervention: Other groups (not specified)
Number of subjects: 51
Study 22933541 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 10 μg/d
Number of subjects: 113
Study 22933541 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 30 μg/d
Number of subjects: 113
Study 22933541 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 40 μg/d
Number of subjects: 113
Study 22933541 — intervention group
Group type: COMPARATOR
Intervention: Control (10 μg/d)
Number of subjects: 113
Study 22933541 — intervention group
Group type: COMPARATOR
Intervention: Control (30 μg/d)
Number of subjects: 113
Study 22933541 — intervention group
Group type: COMPARATOR
Intervention: Control (40 μg/d)
Number of subjects: 113
Study 20816189 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 318
Study 20816189 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone Propionate (FP)
Number of subjects: 318
Study 18453796 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/d
Number of subjects: 9739
Study 18453796 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d
Number of subjects: 9739
Study 18453796 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP < 140 mm Hg
Number of subjects: 9739
Study 18453796 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest LDL-C tertile with SBP < 140 mm Hg
Number of subjects: 9739
Study 18453796 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest LDL-C tertile
Number of subjects: 9739
Study 15722809 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain intensity (100 mm Visual Analog Scale [VAS])
Number of subjects: 133
Study 15722809 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain frequency
Number of subjects: 133
Study 15722809 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily pain duration
Number of subjects: 133
Study 15722809 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain behavior (verbal 6-point scale)
Number of subjects: 133
Study 15722809 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain patterns
Number of subjects: 133